Admescope

AGINKO Research is the premiere CRO for preclinical work in osteoarticular pathologies. We offer a wide range of contract research services to support Drug and Medical Device established companies as well as start-ups and academia. From industry standard protocols to customized research design, our animal models and assays, both on an in vivo or in vitro basis, provide key tools for compound discovery and product development.

Given our expertise, know-how, and network in the field of osteoarticular pathologies, AGINKO today also offers a full range of histology services for your preclinical and clinical trials as well as general consulting services (e.g., regulatory, strategy, financing) devoted to osteoarticular pathologies.


#Osteoarticular #CRO #Cartilage #Repair #Arthritis #Fracture #Osteoporosis #Preclinical #Pain #Disc #Spine #Infection

There are several GLP-compliant non-clinical CRO’s. Why choose the Aurigon Group?
• We're big enough to provide a full service, but small enough to fully adapt to your needs
• Our qualified staff consists of 70+ professionals, with even 30+ years of experience
• Our proven track record of more than 5700 studies gives us a solid base to serve your needs
• Our flexible approach and your direct contact to the Study Director gives you full control of your study

Aurigon offers a full range of in vivo and in vitro non-clinical services from development candidate to marketed product. These services include, but are not limited to: PK/PD, ADME, bioanalytics, toxicology and safety pharmacology in all species used in toxicity testing ranging from mouse to minipig.

For our clients we provide tailor-made services on a variety of test item classes including NCE, NBE, herbal extracts, vaccines, medical devices to name a few. We intend to build up long-term partnerships by acting as a problem-solver in our partners’ projects; keeping their budget, timeline and goals in mind.

Aurigon shares its expert knowledge and performs GxP training services (GLP, GMP for batch release assays, GcLP). Our clients will benefit from our comprehensive experience and get new insight into the GxP regulated environment.

As Central European Center for Minipig Research we possess a spacious site as well as sound professional experience for minipig testing. This is accompanied by facilities for small and large animal testing (rodents, rabbits, dogs, ...) as well as in vitro laboratories close to the city borders of Budapest. Furthermore, we maintain a well-equipped bioanalytical department in Budapest.

For more detailed information about our broad service portfolio you may also visit our website (www.aurigon.eu).

Get in touch and let us foster your project a wing stroke ahead!

Studies are performed by our sister company, ATRC Aurigon Toxicological Research Center Ltd.

BioTalentum Ltd. is a leading technology provider in Central & Eastern Europe since 2005.
Our mission is developing and providing human stem cell-based solutions for diseases modelling, in vitro toxicology and regenerative medicine.
The project and management support branch of Biotalentum ltd. is Biotalentum Consultancy with 15 years experience in FP6, FP7 and H2020 proposal submission, offers wide range of services in project writing, management and training to support you during the execution of your project.

BrainPlotting is a french contract research organization company which offers his knowledge to predict the entrance of drugs into the brain
To that end BrainPlotting developped in vitro models based on fresh human tissus and cells.
BrainPlotting is incubated at the Brain and Spine Institute (ICM), Paris, France

Our core business is the study of pharmacokinetics (PK) in the human brain. The molecules that we study can have CNS targets as well as peripheral targets.
To study the brain's PK, BrainPlotting uses the most accurate predictive models and the most recent methods and tools. To generate the highest-accuracy predictive models, BrainPlotting developed proprietary in vitro models based on primary human cells.

PK predictions can be made at various stages of the molecules'​ development (e.g. screening, Hit-to-Lead, lead optimization) by using a variety of methods, such as:
· Evaluation of the blood-brain barrier permeability from absorption (blood to brain) to elimination (brain to blood)
· Determination of the unbound fraction of the drug in the blood and in the brain
· Estimation of the drug concentration in the brain in both ECF and ICF in fresh human brain slices
· Modeling the human in vivo concentration based on human in vitro data

Crescendo Biologics is a biopharmaceutical company developing conditionally-activated T cell enhancing therapeutics, with a particular focus on CD137 (4-1BB).

The innovative, first and best in class programmes are designed to activate only tumour-specific T cells in the tumour micro-environment and not outside it. This approach is expected to reduce the toxicities experienced with traditional immunotherapies and also to lead to the proliferation of tumour-specific T cells with a broad, long-lasting anti-tumour response.

Our lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific for PSMA-positive tumours. CB307’s unique format delivers highly potent tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA-positive cancer indications.

Crescendo’s pipeline is underpinned by its novel, patent-protected Humabody® platform, which generates fully human VH domains (Humabodies). Humabodies are matured in vivo in the absence of any light-chains and are robust and stable molecules. Humabody VH domains can be easily assembled into multi-specific formats which can access novel biology and deliver superior tumour accumulation and penetration compared to conventional monoclonal antibody-based approaches.

The Humabody platform has received third party validation through its strategic, multi-target collaboration in immuno-oncology, ADCs and CAR-Ts with Takeda, worth up to $790M, and from licensing its first programme for an inflammatory target to Zai Lab in 2018. In 2020 Crescendo entered into a Clinical Development Partnership with Cancer Research UK to progress CB213, a PD-1 x LAG-3 bispecific, into the clinic.

Crescendo is progressing novel Humabody®-based product opportunities, through in-house development and strategic collaborations as well as seeking strategic partners to develop novel Humabody therapeutics leveraging our in-house expertise and our pipeline of Humabody molecules.